Atea Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 30, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-10-29

Reporting Person: Vavricka John (Chief Commercial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Convertible Preferred Stock	$		Common Stock (82508)		Indirect
Stock Option (Right to Buy)	$1.43	2028-12-13	Common Stock (200000)		Direct
Stock Option (Right to Buy)	$1.85	2029-12-12	Common Stock (30000)		Direct
Stock Option (Right to Buy)	$6.83	2030-08-02	Common Stock (160000)		Direct

Footnotes

F1: Each share of Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

F2: The option vests and becomes exercisable as to 8,333 shares immediately and as to the remaining shares, in 46 equal monthly installments beginning on December 31, 2018.

F3: The option vests and becomes exercisable in 48 equal monthly installments following November 30, 2019.

F4: The option vests and becomes exercisable in 48 equal monthly installments following June 30, 2020.